<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03493503</url>
  </required_header>
  <id_info>
    <org_study_id>NL55029.078.16</org_study_id>
    <nct_id>NCT03493503</nct_id>
  </id_info>
  <brief_title>Status Asthmaticus on the PICU; Intravenous Salbutamol</brief_title>
  <acronym>STATIC IV</acronym>
  <official_title>Efficacy of a Loading Dose of IV Salbutamol in Children Admitted to a PICU for Severe Acute Asthma or Severe Acute Wheeze</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although IV salbutamol is frequently used in children in a wide range, pharmacodynamic data&#xD;
      are scarce. To date, there is an insufficient evidence base to guide initial and subsequent&#xD;
      dosing recommendation for its IV use in children. Especially the need for a loading dose&#xD;
      needs to be addressed. Therefore, pharmacodynamic and kinetic data are needed to guide&#xD;
      initial dosing strategies of IV salbutamol in children. To assess the efficacy of a loading&#xD;
      dose of intravenous salbutamol in children admitted to a PICU for severe acute wheeze or&#xD;
      severe acute asthma. Efficacy is measured by the reduction in asthma score (Qureshi) at 1&#xD;
      hour after administration of the loading dose, compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 5, 2017</start_date>
  <completion_date type="Actual">May 21, 2019</completion_date>
  <primary_completion_date type="Actual">May 21, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction Asthma score</measure>
    <time_frame>First 24 hours after admission on the PICU</time_frame>
    <description>The primary outcome variable is (reduction of) asthma score (Qureshi) 1 hour after administration of loading dose in the intervention group compared to the placebo group. Based on expert opinion, we consider a reduction of 2 points to represent a clinically relevant improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose of IV salbutamol</measure>
    <time_frame>Through study completion, an average 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum infusion rate of IV salbutamol in mcg/kg/min</measure>
    <time_frame>Through study completion, an average 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration of IV salbutamol treatment in hours</measure>
    <time_frame>Through study completion, an average 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence/frequency of side effects</measure>
    <time_frame>Through study completion, an average 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay on PICU in days</measure>
    <time_frame>Through study completion, an average 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of co-medication</measure>
    <time_frame>Through study completion, an average 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of/duration of non-invasive mechanical ventilation in days</measure>
    <time_frame>Through study completion, an average 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DNA polymorphism of the ADRB2-receptor gene</measure>
    <time_frame>Through study completion, an average 1 year</time_frame>
    <description>The investigators will look at DNA, if there is a polymorphism in the ADRB2-receptor gene. If there is a polymorphism it can cause downregulation of the adrenergic B2 receptors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of/duration of non-invasive/invasive mechanical ventilation in days</measure>
    <time_frame>Through study completion, an average 72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Childhood Asthma With Status Asthmaticus</condition>
  <arm_group>
    <arm_group_label>Salbutamol loading dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salbutamol loading dose of 15 mcg/kg in 10 minutes, with a maximum of 750 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Chloride 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 ml of Sodium Chloride 0.9% in 10 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol</intervention_name>
    <description>Intravenous Salbutamol loading dose</description>
    <arm_group_label>Salbutamol loading dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride 0.9%</intervention_name>
    <description>10 ml of Sodium Chloride 0.9% in 10 minutes intravenous</description>
    <arm_group_label>Sodium Chloride 0.9%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 2-18 years of age at moment of inclusion&#xD;
&#xD;
          -  Admitted to PICU for Severe Acute Asthma or Severe acute (viral) wheeze&#xD;
&#xD;
          -  Requiring administration of IV salbutamol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is outside of specified age range&#xD;
&#xD;
          -  Patient has already received a -loading dose- of IV salbutamol in the general hospital&#xD;
&#xD;
          -  Lower airway infection with consolidation on a chest X ray -Patient has Down's&#xD;
             Syndrome&#xD;
&#xD;
          -  Patient has a congenital/acquired heart defect that interferes with normal asthma&#xD;
             treatment&#xD;
&#xD;
          -  Patient has a primary/secondary immunodeficiency&#xD;
&#xD;
          -  Patient has a pre-existing chronic pulmonary condition, known to mimic asthma: Cystic&#xD;
             fibrosis, Bronchopulmonary dysplasia, Bronchiolitis obliterans&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3000WB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Matthijs de Hoog</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Status Asthmaticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

